Cargando…

Erratum to cancer cachexia syndrome and clinical outcome in patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors: results from a prospective, observational study

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2023
Materias:	Erratum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10654439/ https://www.ncbi.nlm.nih.gov/pubmed/38025815 http://dx.doi.org/10.21037/tlcr-2023-3

Ejemplares similares

Cancer cachexia syndrome and clinical outcome in patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors: results from a prospective, observational study
por: Rounis, Konstantinos, et al.
Publicado: (2021)

Erratum to evaluation of PD-L1 expression on circulating tumour cells in small cell lung cancer
Publicado: (2022)

Erratum: PD-1/PD-L1 Pathway Mediates the Alleviation of Pulmonary Fibrosis by Human Mesenchymal Stem Cells in Humanized Mice
Publicado: (2021)

Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer(1)
Publicado: (2020)

Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer
Publicado: (2021)

Erratum to: Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance
por: Pelekanou, Vasiliki, et al.
Publicado: (2017)

Erratum: Electric-field control of magnetic moment in Pd
por: Obinata, Aya, et al.
Publicado: (2015)

Erratum to: Recent developments in the treatment of cachexia: highlights from the 6th Cachexia Conference
por: Ebner, N., et al.
Publicado: (2012)

Effect of body tissue composition on the outcome of patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors
por: Makrakis, Dimitrios, et al.
Publicado: (2023)

Correction: Effect of body tissue composition on the outcome of patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors
por: Makrakis, Dimitrios, et al.
Publicado: (2023)

PD-1/PD-L1 inhibitors for advanced or metastatic cervical cancer: From bench to bed
por: Huang, Weijia, et al.
Publicado: (2022)

Erratum: SOCS1 favors the epithelial-mesenchymal transition in melanoma, promotes tumor progression and prevents antitumor immunity by PD-L1 expression
por: Berzaghi, R., et al.
Publicado: (2017)

Herpes zoster in lung cancer patients treated with PD-1/PD-L1 inhibitors
por: Taoka, Masataka, et al.
Publicado: (2022)

PD-1/PD-L1 Inhibitors in Cervical Cancer
por: Liu, Yuncong, et al.
Publicado: (2019)

Atypical Response in Metastatic Non-Small Cell Lung Cancer Treated with PD-1/PD-L1 Inhibitors: Radiographic Patterns and Clinical Value of Local Therapy
por: Jiang, Shanshan, et al.
Publicado: (2022)

Review of PD-1/PD-L1 Inhibitors in Metastatic dMMR/MSI-H Colorectal Cancer
por: Oliveira, André F., et al.
Publicado: (2019)

Real‐world utilization of PD‐1/PD‐L1 inhibitors with palliative radiotherapy in patients with metastatic non‐small cell lung cancer
por: Zhou, Zi‐Chao, et al.
Publicado: (2022)

Erratum to: Neonatal Hyperbilirubinemia in infants with G6PD c.563C > T Variant
por: Moiz, Bushra, et al.
Publicado: (2016)

Erratum to: Evolving Approaches to Metastatic Breast Cancer Patients Pre-treated with Anthracycline and Taxane
por: Saji, Shigehira
Publicado: (2013)

Real-world evidenceand clinical observations of the treatment of advanced non-small cell lung cancer with PD-1/PD-L1 inhibitors
por: Song, Peng, et al.
Publicado: (2019)

Overcoming resistance to PD-1/PD-L1 inhibitors in esophageal cancer
por: Cheng, Chao, et al.
Publicado: (2022)

Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis
por: Shen, Xian, et al.
Publicado: (2018)

Erratum to: A case report of Grover’s disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1
por: Uemura, Marc, et al.
Publicado: (2017)

In vitro characterization of a small molecule PD-1 inhibitor that targets the PD-l/PD-L1 interaction
por: Lu, Chih-Hao, et al.
Publicado: (2022)

Cellular engagement and interaction in the tumor microenvironment predict non-response to PD-1/PD-L1 inhibitors in metastatic non-small cell lung cancer
por: Qin, Angel, et al.
Publicado: (2022)

Brain metastases, patterns of intracranial progression, and the clinical value of upfront cranial radiotherapy in patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors
por: Guo, Tiantian, et al.
Publicado: (2022)

Changes in expression of PD-L1 on peripheral T cells in patients with melanoma and lung cancer treated with PD-1 inhibitors
por: Dart, Sarah J., et al.
Publicado: (2021)

Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab
por: Nicolazzo, Chiara, et al.
Publicado: (2016)

The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer
por: Qu, Jingjing, et al.
Publicado: (2021)

Erratum. PD-L1–Driven Tolerance Protects Neurogenin3-Induced Islet Neogenesis to Reverse Established Type 1 Diabetes in NOD Mice. Diabetes 2015;64:529—540
por: Li, Rongying, et al.
Publicado: (2015)

PD-1/PD-L1 inhibitors as a hope for smokers of non-small cell lung cancer patient
por: Yu, Zhuo, et al.
Publicado: (2019)

Currently Used Laboratory Methodologies for Assays Detecting PD-1, PD-L1, PD-L2 and Soluble PD-L1 in Patients with Metastatic Breast Cancer
por: Jeong, Seri, et al.
Publicado: (2021)

PD-1/PD-L1 Inhibitor Plus Chemotherapy Versus PD-1/PD-L1 Inhibitor in Microsatellite Instability Gastrointestinal Cancers: A Multicenter Retrospective Study
por: Chen, Mifen, et al.
Publicado: (2023)

Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells
por: Skalniak, Lukasz, et al.
Publicado: (2017)

Molecular Mechanism of Small-Molecule Inhibitors in Blocking the PD-1/PD-L1 Pathway through PD-L1 Dimerization
por: Guo, Yan, et al.
Publicado: (2021)

Erratum to: Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer
por: Bendell, Johanna C., et al.
Publicado: (2015)

The Latest Findings of PD-1/PD-L1 Inhibitor Application in Gynecologic Cancers
por: Kooshkaki, Omid, et al.
Publicado: (2020)

Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy
por: Ai, Leilei, et al.
Publicado: (2020)

Efficacy and safety of adjuvant therapy with PD‑1/PD‑L1 inhibitors in cancer
por: Mo, Dun-Chang, et al.
Publicado: (2022)

PD-L1 expression as biomarker of efficacy of PD-1/PD-L1 checkpoint inhibitors in metastatic triple negative breast cancer: A systematic review and meta-analysis
por: Khan, Muhammad, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_92dno51bqfjr41a7o0rp2c5tcg